SCHEMBL7182502

SCHEMBL7182502

COc1ccc(Cl)c(OC)c1P(=O)(C(=O)c1ccccc1)C(=O)c1c(C)cc(C)cc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 3/20 0.41
TAS1R1 Q7RTX1 3/20 0.41
TAS1R2 Q8TE23 3/20 0.41
ATM Q13315 1/20 0.40
SMO Q99835 3/20 0.38
ALDH1A1 P00352 2/20 0.38
KMT2A Q03164 3/20 0.38
KDM4E B2RXH2 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PKM P14618 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MEN1 O00255 1/20 0.36
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36
TUBB4B P68371 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7178067 0.91 ALDH1A1 (0.39) TAS1R3TAS1R1TAS1R2ATMSMO
SCHEMBL7182641 0.91 ATM (0.38) TAS1R3TAS1R1TAS1R2ATMSMO
SCHEMBL7174658 0.89 ATM (0.38) TAS1R3TAS1R1TAS1R2ATMSMO
SCHEMBL7189530 0.87 ALDH1A1 (0.40) TAS1R3TAS1R1TAS1R2ATMSMO
SCHEMBL7177486 0.87 HPGD (0.43) ATMSMOALDH1A1KMT2APKM
SCHEMBL7182401 0.87 MEN1 (0.40) ATMALDH1A1KMT2AKDM4ERAB9A
SCHEMBL7175435 0.86 ALDH1A1 (0.40) TAS1R3TAS1R1TAS1R2ATMSMO
SCHEMBL7187072 0.86 ALDH1A1 (0.43) TAS1R3TAS1R1TAS1R2ATMSMO
SCHEMBL7186421 0.86 ATM (0.40) TAS1R3TAS1R1TAS1R2ATMSMO
SCHEMBL7175781 0.85 TAS1R3 (0.40) TAS1R3TAS1R1TAS1R2ATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 TAS1R3 2990/4885TAS1R1 3374/4885TAS1R2 3865/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 TAS1R3 3176/4885TAS1R1 3927/4885TAS1R2 4103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.